Delaware
|
11-2644611
|
|
(State
or other jurisdiction
|
(IRS
Employer Identification No.)
|
|
Of
incorporation or organization)
|
||
Contents
|
|
Part
I:
|
Financial
Information
|
Item
1:
|
Consolidated
Financial Statements
|
Consolidated
Balance Sheet - June 30, 2005 And December 31, 2004
|
|
Consolidated
Statements of Operations for the three Months Ended June 30, 2005
and
2004
|
|
Consolidated
Statements of Operations for the six Months Ended June 30, 2005
and
2004
|
|
Consolidated
Statement of Shareholders' Equity for the period January 1, 2004
to June
30, 2005
|
|
Consolidated
Statements of Cash Flows for the six Months Ended June 30, 2005
and
2004
|
|
Notes
to Financial Statements
|
|
Item
2:
|
Management's
Discussion and Analysis
|
Part
II.
|
Other
Information
|
Item
1:
|
Legal
Proceedings
|
Item
2:
|
Unregistered
Sales of Equity Securities and use of Proceeds
|
Item
3:
|
Defaults
Upon Senior Securities
|
Item
4:
|
Submission
of Matters to Vote of Security Holders
|
Item
5:
|
Other
Information
|
Item
6:
|
Exhibits
|
BOVIE
MEDICAL CORPORATION
|
|||||||
CONSOLIDATED
BALANCE SHEET
|
|||||||
JUNE
30, 2005 AND DECEMBER 31, 2004
|
|||||||
Assets
|
|||||||
(Unaudited)
|
(Audited)
|
||||||
June
30, 2005
|
December
31, 2004
|
||||||
Current
assets:
|
|||||||
Cash
|
$
|
1,090,376
|
$
|
2,294,746
|
|||
Trade
accounts receivable
|
2,541,639
|
1,954,287
|
|||||
Inventories
|
2,517,818
|
2,001,637
|
|||||
Prepaid
expenses
|
314,329
|
328,765
|
|||||
Deferred
tax asset
|
386,200
|
386,200
|
|||||
Other
receivables
|
55,000
|
--
|
|||||
Total
current assets
|
6,905,362
|
6,965,635
|
|||||
Property
and equipment, net
|
2,570,783
|
2,116,324
|
|||||
Other
assets:
|
|||||||
Repair
parts
|
63,779
|
124,363
|
|||||
Brand
name/Trademark
|
1,509,662
|
1,509,662
|
|||||
Patent
rights, net
|
60,375
|
88,572
|
|||||
License
Rights, net
|
323,334
|
350,000
|
|||||
Deposits
|
16,445
|
14,445
|
|||||
1,973,595
|
2,087,042
|
||||||
$
|
11,449,740
|
$
|
11,169,001
|
||||
The
accompanying notes are an integral part of the financial
statements.
|
BOVIE
MEDICAL CORPORATION
|
|||||||
CONSOLIDATED
BALANCE SHEET
|
|||||||
JUNE
30, 2005 AND DECEMBER 31, 2004
|
|||||||
(CONTINUED)
|
|||||||
Liabilities
and Stockholders' Equity
|
|||||||
(Unaudited)
|
(Audited)
|
||||||
June
30, 2005
|
December
31, 2004
|
||||||
Current
liabilities:
|
|||||||
Accounts
payable
|
$
|
727,151
|
$
|
620,151
|
|||
Accrued
expense
|
717,863
|
568,482
|
|||||
Deferred
Revenue
|
132,023
|
157,844
|
|||||
Customer
deposits
|
107,211
|
36,000
|
|||||
Current
maturities of long-term debt
|
31,668
|
31,668
|
|||||
Total
current liabilities
|
1,715,916
|
1,414,145
|
|||||
Long
Term Liabilities
|
332,494
|
348,325
|
|||||
Minority
interest
|
145,000
|
150,000
|
|||||
Stockholders'
equity:
|
|||||||
Preferred
Stock, par value $.001
10,000,000
shares authorized
0
issued and outstanding on June 30, 2005 and December 31,
2004
|
--
|
--
|
|||||
Common
stock par value $.001; 40,000,000 shares authorized, issued and
outstanding 13,909,858 shares and 13,897,858 shares on June 30,
2005 and
|
|||||||
December
31, 2004 respectively
|
13,928
|
13,881
|
|||||
Additional
paid in capital
|
20,420,473
|
20,391,407
|
|||||
Accumulated
deficit
|
(11,178,071
|
)
|
(11,148,757
|
)
|
|||
Total
stockholders' equity
|
9,256,330
|
9,256,531
|
|||||
Total
liabilities and stockholders' equity
|
$
|
11,449,740
|
$
|
11,169,001
|
|||
The
accompanying notes are an integral part of the financial statements.
|
BOVIE
MEDICAL CORPORATION
|
|||||||||||||
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
|||||||||||||
FOR
THE THREE MONTHS ENDED JUNE 30, 2005 AND 2004 AND FOR THE JUNE
30
|
|||||||||||||
SIX
MONTHS ENDED JUNE 30, 2005 AND 2004
|
|||||||||||||
(UNAUDITED)
|
|||||||||||||
Three
Months Ended June 30,
|
Six
Months Ended June 30,
|
||||||||||||
2005
|
2004
|
2005
|
2004
|
||||||||||
Sales
|
$
|
5,057,912
|
$
|
5,268,863
|
$
|
9,801,123
|
$
|
10,012,821
|
|||||
Cost
of sales
|
3,467,454
|
3,312,611
|
6,560,195
|
6,309,118
|
|||||||||
Gross
Profit
|
1,590,458
|
1,956,252
|
3,240,928
|
3,703,703
|
|||||||||
Costs
and expenses:
|
|||||||||||||
Research
and development
|
174,545
|
215,912
|
354,089
|
361,121
|
|||||||||
Professional
services
|
89,499
|
93,596
|
237,521
|
222,848
|
|||||||||
Salaries
and related costs
|
466,179
|
465,343
|
887,651
|
907,460
|
|||||||||
Selling,
general and administrative
|
955,008
|
765,914
|
1,733,303
|
1,545,593
|
|||||||||
Development
joint venture
|
30,579
|
7,500
|
73,882
|
15,968
|
|||||||||
1,715,810
|
1,548,265
|
3,286,446
|
3,051,990
|
||||||||||
Gain/(loss)
from operations
|
(
125,352
|
)
|
407,987
|
(
45,518
|
)
|
651,713
|
|||||||
Other
income (expense):
|
|||||||||||||
Interest
(net of income)
|
4,515
|
(3,440
|
)
|
11,204
|
(7,337
|
)
|
|||||||
Income
(loss)
|
(120,837
|
)
|
404,547
|
(34,314
|
)
|
644,376
|
|||||||
Provision
for income tax
|
--
|
(139,192
|
)
|
--
|
(225,532
|
)
|
|||||||
Realized
benefit of loss carryforward
|
--
|
139,192
|
--
|
225,532
|
|||||||||
Net
income/(loss) before minority interest
|
$
|
(
120,837
|
)
|
$
|
404,547
|
$
|
(
34,314
|
)
|
$
|
644,376
|
|||
Minority
interest
|
2,500
|
--
|
5,000
|
--
|
|||||||||
Net
Income (loss)
|
$
|
(
118,337
|
)
|
$
|
404,547
|
$
|
29,314
|
$
|
644,376
|
||||
Earnings
per share/(loss)
|
|||||||||||||
Net
income:
|
|||||||||||||
Basic/(loss)
|
(.01
|
)
|
.03
|
(.00
|
)
|
.05
|
|||||||
Diluted
|
N/A
|
.03
|
N/A
|
.04
|
|||||||||
Weighted
average number of shares outstanding
|
13,908,188
|
13,762,430
|
13,897,055
|
13,664,419
|
|||||||||
Weighted
average number of shares outstanding adjusted for dilutive securities
|
N/A
|
16,024,195
|
N/A
|
16,048,888
|
|||||||||
The
accompanying notes are an integral part of the financial
statements.
|
BOVIE
MEDICAL CORPORATION
|
|||||||||||||||||||
CONSOLIDATED
STATEMENT OF SHAREHOLDERS' EQUITY
|
|||||||||||||||||||
FOR
THE PERIOD ENDED JANUARY 1, 2004 TO JUNE 30, 2005
|
|||||||||||||||||||
Options
|
Common
|
Paid-in
|
|||||||||||||||||
Outstanding
|
Shares
|
Value
|
Capital
|
Deficit
|
Total
|
||||||||||||||
January
1, 2004
|
3,988,800
|
13,464,528
|
$
|
13,482
|
$
|
20,097
|
$
|
(12,660,750
|
)
|
$
|
7,449,827
|
||||||||
Options
granted
|
370,000
|
--
|
--
|
--
|
--
|
--
|
|||||||||||||
Options
exercised
|
(397,600
|
)
|
397,600
|
399
|
294,312
|
--
|
294,711
|
||||||||||||
Options
forfeited
|
(
10,000
|
)
|
--
|
--
|
--
|
--
|
--
|
||||||||||||
Income
for period
|
--
|
--
|
--
|
--
|
1,511,993
|
1,511,993
|
|||||||||||||
December
31, 2004
|
3,951,200
|
13,862,128
|
$
|
13,881
|
$
|
20,391407
|
$
|
(11,148,757
|
)
|
$
|
9,256,531
|
||||||||
Options
exercised
|
(47,730
|
)
|
(
47,730
|
)
|
47
|
29,066
|
--
|
29,113
|
|||||||||||
Loss
for period
|
--
|
--
|
--
|
--
|
(
29,314
|
)
|
(29,314
|
)
|
|||||||||||
June
30, 2005
|
3,903,470
|
13,909,858
|
$
|
13,928
|
$
|
20,420,473
|
$
|
(11,178,071
|
)
|
$
|
9,256,330
|
||||||||
The
accompanying notes are an integral part of the financial
statements.
|
BOVIE
MEDICAL CORPORATION AND SUBSIDIARIES
|
|||||||
CONSOLIDATED
STATEMENT OF CASH FLOWS
|
|||||||
INCREASE
(DECREASE) IN CASH AND CASH EQUIVALENTS
|
|||||||
FOR
THE SIX MONTHS ENDED JUNE 30, 2005 AND 2004
|
|||||||
(UNAUDITED)
|
|||||||
2005
|
2004
|
||||||
Cash
flows from operating activities
|
|||||||
Net
income( loss)
|
$
|
(
29,314
|
)
|
$
|
644,376
|
||
Adjustments
to reconcile net income to net cash provided by (used in) operating
activities:
|
|||||||
Depreciation
and amortization
|
254,081
|
193,070
|
|||||
Changes
in current assets and liabilities:
|
|||||||
Receivables
|
(
587,352
|
)
|
(
575,044
|
)
|
|||
Inventories
and repair parts
|
(
455,597
|
)
|
90,833
|
||||
Prepaid
expenses
|
14,436
|
195,899
|
|||||
Other
receivable
|
(
55,000
|
)
|
|||||
Accounts
payable
|
178,210
|
209,866
|
|||||
Accrued
expense
|
149,381
|
64,407
|
|||||
Deferred
Revenue
|
(25,821
|
)
|
37,004
|
||||
Net
cash provided (applied) by operating activities
|
(
556,976
|
)
|
860,411
|
||||
Cash
flows from investing activities
|
|||||||
Increase
in fixed assets
|
(
656,675
|
)
|
(
525,208
|
)
|
|||
Increase
in deposits
|
(
2,000
|
)
|
3,359
|
||||
Patents
|
(
2,001
|
)
|
(
2,001
|
)
|
|||
Net
cash used in investing activities
|
(660,676
|
)
|
(523,850
|
)
|
|||
Cash
flows from financing activities
|
|||||||
(Decrease)
in mortgage payable
|
(
15,831
|
)
|
(
19,507
|
)
|
|||
Common
shares purchased
|
29,113
|
252,425
|
|||||
Obligations
from shareholders
|
--
|
2,708
|
|||||
Net
cash provided in financing activities
|
13,282
|
235,626
|
|||||
Net
increase (decrease) in cash and cash equivalents
|
(1,204,370
|
)
|
572,187
|
||||
Cash
and cash equivalents, beginning of period
|
2,294,746
|
306,137
|
|||||
Cash
and cash equivalents, end of period
|
$
|
1,090,376
|
$
|
878,324
|
|||
The
accompanying notes are an integral part of the financial
statements.
|
|
2005
|
2004
|
|||||
Interest
paid
|
$
|
10,675
|
$
|
7,450
|
|||
Income
taxes
|
-
0
-
|
-
0
-
|
June
30, 2005
|
December
31, 2004
|
||||||
Raw
materials
|
$
|
776,803
|
$
|
705,188
|
|||
Work
in process
|
1,108,377
|
742,289
|
|||||
Finished
goods
|
632,638
|
554,160
|
|||||
Total
|
$
|
2,517,818
|
$
|
2,001,637
|
June
30, 2005
|
December
31, 2004
|
||||||
Raw
materials/Repair parts
|
$
|
63,779
|
$
|
124,363
|
June
30, 2005
|
December
31, 2004
|
||||||
Indefinite
life assets:
|
|||||||
Brand
name/Trademark (life indefinite)
|
$
|
1,509,662
|
$
|
1,509,662
|
|||
Other
intangibles:
|
|||||||
License
rights (20 yr life)
|
$
|
400,000
|
$
|
400,000
|
|||
Less:
Accumulated amortization
|
76,666
|
(
50,000
|
)
|
||||
Net
carrying amount
|
323,334
|
350,000
|
|||||
Purchased
technology (5 yr life)
|
280,764
|
278,763
|
|||||
Less:
Accumulated amortization
|
(220,389
|
)
|
(190,191
|
)
|
|||
Net
carrying amount
|
$
|
60,375
|
$
|
88,572
|
Six
months ended June 30 (000 omitted)
|
|||||||
2005
|
2004
|
||||||
Net
income (loss)
|
$
|
(29
|
)
|
$
|
--
|
||
Basic-weighted
average shares outstanding
|
13,897
|
13,133
|
|||||
Effect
of dilutive potential securities
|
N/A
|
581
|
|||||
Diluted
- weighted average shares outstanding
|
N/A
|
13,714
|
|||||
Basic
EPS
|
$
|
(.01
|
)
|
$
|
.04
|
||
Diluted
EPS
|
$
|
N/A
|
$
|
.03
|
Percentage
|
Percentage
|
||||||||||||||||||
Change
in
|
Change
in
|
||||||||||||||||||
Quarter
|
Dollar
amounts
|
Six
months
|
Dollar
amounts
|
||||||||||||||||
2005
|
2004
|
2005
|
2004
|
||||||||||||||||
% | % | % | % | % |
%
|
||||||||||||||
Sales
|
100.0
|
100.0
|
(4.0
|
)
|
100.0
|
100.0
|
(2.0
|
)
|
|||||||||||
Cost
of sales
|
69.0
|
63.0
|
5.0
|
67.0
|
63.0
|
4.0
|
|||||||||||||
Gross
profit
|
31.0
|
37.0
|
(19.0
|
)
|
33.0
|
37.0
|
(12.0
|
)
|
|||||||||||
Other
costs:
|
|||||||||||||||||||
R
& D
|
3.0
|
4.0
|
(20.0
|
)
|
4.0
|
4.0
|
(2.0
|
)
|
|||||||||||
Professional
fees
|
2.0
|
2.0
|
(4.0
|
)
|
2.0
|
2.0
|
7.0
|
||||||||||||
Salaries
|
9.0
|
9.0
|
0.0
|
9.0
|
9.0
|
(2.0
|
)
|
||||||||||||
SGA
|
19.0
|
15.0
|
25.0
|
18.0
|
15.0
|
12.0
|
|||||||||||||
Equity
in loss of Unconsolidated affiliate
|
1.0
|
0.0
|
274.0
|
1.0
|
0.0
|
331.0
|
|||||||||||||
Total
other costs
|
34.0
|
29.0
|
11.0
|
33.0
|
30.0
|
7.0
|
|||||||||||||
Income
form operations(loss)
|
(2.0
|
)
|
8.0
|
(130.0
|
)
|
0.0
|
7.0
|
(106.0
|
)
|
||||||||||
Other
expense
|
0.00
|
0.0
|
(130.0
|
)
|
0.0
|
0.0
|
0.0
|
||||||||||||
Net
Income
|
(2.0
|
)
|
8.0
|
(130.0
|
)
|
0.0
|
0.0
|
(106.0
|
)
|
||||||||||
Income
tax expense
|
(
3.0
|
)
|
|||||||||||||||||
Income
tax benefit
|
|
3.0
|
|
|
|
|
|||||||||||||
Net
earnings
|
(2.0
|
)
|
(8.0
|
)
|
(130.0
|
)
|
0.00
|
0.0
|
(106.0
|
)
|
Net
Sales (in thousands)
|
Percentage
change
|
Increase/
|
|||||||||||
2005
|
2004
|
2005/2004
|
(Decrease)
|
||||||||||
Domestic/international
sales:
|
|||||||||||||
Domestic
|
$
|
4,519
|
$
|
4,522
|
0
|
(3
|
)
|
||||||
International
|
539
|
747
|
(28
|
)
|
(208
|
)
|
|||||||
Total
net sales
|
$
|
5,058
|
$
|
5,269
|
(.04
|
)
|
(
211
|
)
|
|||||
Product
line sales:
|
|||||||||||||
Electrosurgical
|
$
|
2,987
|
$
|
3,471
|
(14
|
)
|
(484
|
)
|
|||||
Cauteries
|
1,272
|
1,269
|
0
|
3
|
|||||||||
Other
|
799
|
529
|
51
|
270
|
|||||||||
Total
net sales
|
$
|
5,058
|
$
|
5,269
|
(.04
|
)
|
(
211
|
)
|
Net
Sales (in thousands)
|
Percentage
change
|
Increase/
|
|||||||||||
2005
|
2004
|
2005/2004
|
(Decrease)
|
||||||||||
Domestic/international
sales:
|
|||||||||||||
Domestic
|
$
|
8,534
|
$
|
8,585
|
1.0
|
(
51
|
)
|
||||||
International
|
1,267
|
1,428
|
11.0
|
(161
|
)
|
||||||||
Total
net sales
|
$
|
9,801
|
$
|
10,013
|
2.0
|
(212
|
)
|
||||||
Product
line sales:
|
|||||||||||||
Electrosurgical
|
$
|
5,498
|
$
|
6,328
|
(13
|
)
|
(830
|
)
|
|||||
Cauteries
|
2,602
|
2,527
|
3.0
|
75
|
|||||||||
Other
|
1,701
|
1,158
|
47.0
|
543
|
|||||||||
Total
net sales
|
$
|
9,801
|
$
|
10,013
|
(2.0
|
)
|
(
212
|
)
|
|
Six
Months
|
|
Payment
Period
|
|
||||||||||||
2005
|
2006
|
2007
|
2008
|
2009
|
||||||||||||
Long-term
debt
|
$
|
16
|
$
|
348
|
$
|
-0-
|
$
|
-0-
|
$
|
-0-
|
||||||
Operating
leases
|
73
|
142
|
135
|
115
|
-0-
|
|||||||||||
Unconditional
purchase obligations
|
2,027
|
681
|
-0-
|
-0-
|
-0-
|
|
Amount
of Commitment
|
|||||||||
Total
|
Expiration
Per Period
|
|||||||||
|
Amount
|
Less
than
|
In
excess of
|
|||||||
|
Committed
|
1
year
|
1
year
|
|||||||
Secured
revolving credit agreement and other lines of credit
|
$
|
1.5
|
$
|
1.5
|
$
|
-0-
|
31.1
|
Certifications
of Andrew Makrides, President and Chief Operating Officer of Registrant
pursuant to Rule 13a-14 adopted under the Securities Exchange Act
of 1934,
as amended, and Section 302 of the Sarbanes-Oxley Act of
2002.
|
31.2
|
Certifications
of Andrew Makrides and acting Chief Financial Officer of Registrant
pursuant to Rule 13a-14 adopted under the Securities Exchange Act
of 1934,
as amended, and Section 302 of the Sarbanes-Oxley act of
2002.
|
32.1
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
the Sarbanes-Oxley Act of 2002.
|
32.2
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
the Sarbanes-Oxley Act of 2002.
|